Drug Topics

MAY 12, 2025

Tirzepatide (Zepbound) demonstrated superiority compared to semaglutide (Wegovy) across the primary end point and 5 key secondary end points.

469

469

PharmaVoice

MAY 12, 2025

While AI-generated drugs grab headlines, the technology is making more of an impact doing less “glamorous” tasks.

147

147

Drug Topics

MAY 12, 2025

Douglas Hoey, CEO of NCPA, discusses what independent pharmacies can do to handle an influx of patients and what the chains situation means for the pharmacy landscape.

Independent Pharmacies 411

Independent Pharmacies 411

STAT

MAY 12, 2025

I’m taking Health and Human Services Secretary Robert F. Kennedy Jr. to court. I don’t want to do it. But I have to do it — not for myself, but to protect science.

133

133

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

MAY 12, 2025

Investigators find that unhealthy eating and inadequate or excessive sleeping duration could contribute to developing diabetic nephropathy.

315

315

STAT

MAY 12, 2025

OpenAI on Monday released a large dataset for evaluating how well large language models answer questions related to health care. Experts lauded the open-source data and detailed evaluation rubrics, calling them “unprecedented” in scale and breadth. The project, HealthBench , marks OpenAI’s first foray into health care applications of AI, outside of external partnerships.

134

134

STAT

MAY 12, 2025

The now 13-year-long legal saga over who invented CRISPR took yet another unexpected turn on Monday, in a ruling that could not only change U.S. ownership of patent rights to the groundbreaking gene-editing technology but more broadly redefine how the law determines when an invention has been made.  The U.S. Court of Appeals for the Federal Circuit sided with the University of California and the University of Vienna in their bid to revive a fight over foundational CRISPR-Cas9 patents that t

114

114

PharmaVoice

MAY 12, 2025

But the therapies will need to prove their worth in the clinic over the next few years.

100

100

Fierce Healthcare

MAY 12, 2025

House Republicans have unveiled their plans to cut federal spending and extend tax cuts, but experts warn that funding the cuts by slashing Medicaid and other entitlements will largely benefit families with higher incomes.

88

88

Pharmacy Times

MAY 12, 2025

A panelist discusses how physicians can collaborate with community pharmacists to enhance respiratory syncytial virus (RSV) vaccine uptake by leveraging pharmacists' expertise in patient education, addressing vaccine hesitancy through empathetic communication, and emphasizing the safety, benefits, and risks of RSV vaccination.

Vaccines 65

Vaccines Communication 65

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

MAY 12, 2025

Good morning. What are the best ice cream shoppes in San Francisco? Brittany Trang asked for recommendations recently in AI Prognosis in advance of this Wednesday’s  Breakthrough Summit West. She got an array of answers (Mitchell’s, Bi-Rite, Salt & Straw, Smitten Ice Cream) but the well-informed STAT crowd thought a few important options (Humphry Slocombe, Uji Time Dessert) were missing.

97

97

Pharmacy Times

MAY 12, 2025

PharmStart empowers pharmacy technicians to pursue their education with tuition-free prerequisites, addressing barriers to entering pharmacy school.

69

69

STAT

MAY 12, 2025

This is the online version of STAT’s email newsletter Health Care Inc., delivered to your inbox every Monday.  Sign up here. Let’s admit it, we’re all enraptured with the Chicago pope content. The deep-dish pizza memes are excellent. But it’s also great the pope actually enjoys Aurelio’s pizza , a tavern-style staple in Chicagoland.

Hospitals 94

Hospitals Insurance 94

Pharmacy Times

MAY 12, 2025

A panelist discusses how physicians can navigate respiratory syncytial virus (RSV) vaccine selection by considering patient age, pregnancy status, and seasonality, highlighting the approved indications for Arexvy and Abrysvo, including maternal immunization to protect infants through passive immunity.

Vaccines 65

Vaccines Immunization 65

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharmafile

MAY 12, 2025

Danish biopharma, Novo Nordisk, has announced that it will present new data on metabolic and cardiovascular health at the upcoming 32nd European Congress on Obesity (ECO). Central to the announcement will be findings related to semaglutide, a GLP-1 receptor agonist developed as a treatment for obesity and related cardiometabolic conditions. Semaglutide will be a key focus, […] The post Novo Nordisk unveils new semaglutide data on obesity and heart disease at ECO 2025 appeared first on Phar

77

77

Pharmacy Times

MAY 12, 2025

Panelists discuss how evidence from a value-based care perspective demonstrates long-term health benefits, including reduced recurrent events and hospitalizations, as well as cost savings associated with intensive low-density lipoprotein cholesterol (LDL-C)lowering therapies beyond statins in patients who are very high-risk post-atherosclerotic cardiovascular disease (ASCVD), while also addressing key challenges health care providers face in selecting nonstatin therapies and strategies to overco

Hospitals 65

Hospitals 65

OctariusRx

MAY 12, 2025

Speaking at the ASCA 2025 Conference & Expo, April 30May 3, in Denver Colorado was a great time. A special thank you Gina Throneberry, Director of Clinical and Educational Affairs for the invitation. My presentation focused on safe medication management through complete pharmacy documentation. I discussed the most common survey issues and provided practical tips for improving patient safety and survey success.

Documentation 80

Documentation 80

Pharmacy Times

MAY 12, 2025

Panelists discuss how patients' access to and preferences for PCSK9 inhibitors and other treatments are influenced by factors such as insurance coverage, administration convenience, financial toxicity, and individual health concerns.

Insurance Coverage 65

Insurance Coverage Insurance 65

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

The Checkup by Singlecare

MAY 12, 2025

MiraLax is a popular brand-name, over-the-counter (OTC) laxative that helps relieve constipation. Containing the active ingredient polyethylene glycol 3350 (PEG 3350), MiraLax is FDA approved to treat occasional constipation in adults. It has several off-label uses, too, including treating chronic constipation, constipation related to irritable bowel syndrome (IBS), bowel preparation for colonoscopy procedures, and treating constipation in children (which the American Academy of Pediatrics consi

Packaging 59

Packaging Labelling FDA 59

Pharma Marketing Network

MAY 12, 2025

Ever tried shouting in a crowded stadium? Thats what it feels like launching a branded healthcare campaign today. With every pharma brand, health system, and startup clamoring for attention, crafting a successful healthcare marketing strategy has never been more challengingor more necessary. In 2025, reaching healthcare professionals (HCPs), patients, and caregivers requires more than budget and brand equity.

64

64

Pharmafile

MAY 12, 2025

The European Commission (EC) has granted Marketing Authorisation (MA) to Johnson & Johnsons Tremfya (guselkumab) for the treatment of moderately to severely active Crohns disease (CD) in adults. The decision follows positive results from two phase 3 programmes, GALAXI and GRAVITI, demonstratingguselkumabs efficacy and safety. Guselkumab became the first approved fully human, dual acting IL-23p19 […] The post European Commission approves Johnson & Johnsons Crohns disease therapy app

64

64

pharmaphorum

MAY 12, 2025

Researchers have developed an AI that could help doctors predict a patient's chance of surviving cancer and potentially guide treatment decisions

59

59

Pharmacy Times

MAY 12, 2025

During a panel discussion, 3 experts highlighted ways health care professionals and researchers can help provide patient-centered care.

50

50

Pharmafile

MAY 12, 2025

Thermosome has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its lead candidate, THE001, a treatment targeting soft tissue sarcomas. The designation, which complements a previous ODD from the European Medicines Agency, affirms the therapys clinical promise and strengthens Thermosomes position in the US pharma market.

FDA 59

FDA 59

Fierce Healthcare

MAY 12, 2025

The already massive nonprofit has grown substantially since the start of last year, though its operating performance and bottom line were both down.

45

45

Pharmafile

MAY 12, 2025

Moderna has expanded its partnership with Benchling, a cloud-based research platform, to support its broader research organisation. Previously used by its technical teams, the platform will now be adopted by scientists across the company as part of efforts to streamline data management and accelerate research workflows. The move reflects a wider shift in the biotech […] The post Moderna expands use of AI-ready R&D platform appeared first on Pharmafile.

59

59

Pharmaceutical Commerce

MAY 12, 2025

The financial decision is due to customer demand stemming from the reshoring of drug supply services.

52

52

Pharmafile

MAY 12, 2025

From prostate cancer to hormonal health, many areas of mens health require more attention. As male life expectancy and healthy lifespan continue to lag behind, Charlie Bryant at Androlabs explores how pharma could help improve this by shifting its focus from treatment to prevention Pharmafile: How important is it to raise awareness about men’s health?

59

59

Pharmacy Times

MAY 12, 2025

While vaccine research and approvals continue to break new ground, use and faith in them are faltering.

Vaccines 50

Vaccines 50

Pharmaceutical Technology

MAY 12, 2025

The new site will support Roche and its unit Genentech's future portfolio of next-generation obesity medicines.

52

52

PharmExec

MAY 12, 2025

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52

52

pharmaphorum

MAY 12, 2025

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival Wegovy from Novo Nordisk.

52

52

Pharmaceutical Technology

MAY 12, 2025

Minghui Pharmaceutical has announced an exclusive licensing and partnership agreement with Qilu Pharmaceutical for MHB088C in Greater China.

52

52